We therefore analyzed a clinical index in lupus individuals in vivo

  • by

We therefore analyzed a clinical index in lupus individuals in vivo. that enhances IDO activity MPO-IN-28 in allogeneic MSCs and that it is associated with IFNGR1/JAK-2/STAT signaling pathways. Intriguingly, bone marrowCderived MSCs from individuals with active lupus demonstrated defective MPO-IN-28 IDO production in response to IFN and allogeneic CD8+ T cell activation. After allogeneic UC-MSC transplantation, serum IDO activity improved in lupus individuals. Conclusion We found a previously unrecognized CD8+ T cell/IFN/IDO axis that mediates the restorative effects of allogeneic MSCs in lupus individuals. Mesenchymal stem cells (MSCs) are non-hematopoietic stem cells (non-HSCs) that can support the function of HSCs in bone marrow (BM). MSCs have been shown to possess regenerative properties and unique immunoregulatory functions that make them a good option for cellular therapy in individuals with autoimmune diseases and chronic swelling (1). We have previously demonstrated that allogeneic BM- and umbilical wire (UC)Cderived MSC transplantation is definitely a safe and effective treatment of active systemic lupus erythematosus (SLE) (2,3) and additional autoimmune diseases, such as systemic sclerosis (4), Sj?gren’s syndrome (5), and myositis (6). Conversely, autologous MSCs from lupus individuals cannot offer restorative benefits due to intrinsic abnormal MPO-IN-28 functions (7C9). However, the mechanisms by which allogeneic MSC transplantation ameliorates SLE remain mainly unfamiliar. It is right now obvious that MSCs exert immunoregulatory properties on numerous immune cells. This includes suppression of T cell proliferation, rules of dendritic cell (DC) maturation and function, modulation of B cell proliferation and terminal differentiation, and rules of natural killer cells and macrophage function (10C12). Many factors are involved in MSC immunomodulation, including but not limited to, production of transforming growth element (TGF), hepatocyte growth element (HGF), prostaglandin E2 (PGE2), interleukin-10 (IL-10), indolamine 2,3-dioxygenase (IDO), nitric oxide (NO), heme oxygenase MPO-IN-28 1 (HO-1), and HLACG (13C16). IDO, which is mainly produced by DCs and macrophages, is an enzyme that degrades the essential amino acid tryptophan and participates in immune Cldn5 tolerance (17,18). In 2004, a study demonstrated that human being MSCs could secrete IDO in vitro in the presence of mixed lymphocyte reaction. The IDO that was secreted by MSCs mediated inhibition of normal T cell proliferation (19). However, other studies possess shown that IDO takes on a dispensable part in human being MSC suppression of T cell proliferation and have instead suggested that HLACG and IL-10 have a cell-contactCdependent part (20). In animal studies, it has been suggested that NO rather than IDO is involved in immunomodulation by MSCs (21). Importantly, the precise mechanisms responsible for the regulatory effects MPO-IN-28 of MSCs in lupus individuals remain unknown. In this study, we identified that high levels of interferon- (IFN), produced mainly by CD8+ T cells in lupus individuals, are a key factor involved in the stimulation of allogeneic UC-MSCs to produce IDO, which can then inhibit the proliferation of T cells from lupus patients. Thus, we uncovered a previously unrecognized CD8+ T cell/IFN/IDO axis that mediates the therapeutic benefit of allogeneic MSCs in lupus. Patients and Methods Lupus patients and healthy subjects Seventy-nine SLE patients and 89 healthy subjects were included in this study. Informed consent was obtained from each subject for the collection of peripheral blood or BM. Clinical study of UC-MSC transplantation among lupus patients was registered with http://ClinicalTrials.gov (identifier: “type”:”clinical-trial”,”attrs”:”text”:”NCT01741857″,”term_id”:”NCT01741857″NCT01741857). Six patients underwent UC-MSC transplantation as previously described (3). This study was approved by the Ethics Committee at The Affiliated Drum Tower Hospital of Nanjing University Medical School and was conducted in accordance with the 1989 Declaration of Helsinki. Antibodies and reagents The following antibodies (to humans) were used in this study: fluorescein isothiocyanate (FITC)Cconjugated anti-human CD3 (OKT3), anti-CD4 (11830), antiCHLACDR (L203), phycoerythrin (PE)Cconjugated anti-human CD4 (11830), allophycocyanin (APC)Cconjugated anti-human CD8 (RPA-T8), CD25 (M-A251), and the respective isotype-matched control antibodies (mouse IgG1 and mouse IgG2a) (all from BD Biosciences); and FITCCconjugated anti-human CD34 (4H11), CD44 (IM7), PE-conjugated anti-human CD45 (HI30), CD29 (TS2/16), CD166 (3A6), CD138 (DL-101), FoxP3 (150D/14), PECCy7Cconjugated FoxP3 (PCH101), APC-conjugated anti-human CD4 (RPA-T4), CD19 (HIB19), PECCy7Cconjugated anti-human IFN (4S.B3), purified anti-human CD3 (OKT3), CD28 (CD28.2), CD40 (5C3) (no azide and low endotoxin) (all from eBioscience). Recombinant human TGF1 and anti-human.